1. Home
  2. GSIW vs AIMD Comparison

GSIW vs AIMD Comparison

Compare GSIW & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSIW

Garden Stage Limited

N/A

Current Price

$14.40

Market Cap

24.2M

Sector

N/A

ML Signal

N/A

Logo Ainos Inc.

AIMD

Ainos Inc.

N/A

Current Price

$1.36

Market Cap

10.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GSIW
AIMD
Founded
2016
1984
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2M
10.6M
IPO Year
2022
2008

Fundamental Metrics

Financial Performance
Metric
GSIW
AIMD
Price
$14.40
$1.36
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
48.3K
23.5K
Earning Date
08-04-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$124,157.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
498.95
52 Week Low
$0.05
$1.26
52 Week High
$38.55
$4.44

Technical Indicators

Market Signals
Indicator
GSIW
AIMD
Relative Strength Index (RSI) 35.90 39.61
Support Level $13.46 $1.31
Resistance Level $18.03 $1.66
Average True Range (ATR) 1.71 0.08
MACD 0.12 -0.01
Stochastic Oscillator 32.12 0.00

Price Performance

Historical Comparison
GSIW
AIMD

About GSIW Garden Stage Limited

Garden Stage Ltd, through its subsidiaries is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; asset management services; investment advisory services; due diligence services; and introduction and referral services. The company operates in a single segment and derives all of its revenue from Hong Kong.

About AIMD Ainos Inc.

Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.

Share on Social Networks: